PDCD1 and cancer: PD-L1-neutralizing antibodies, including atezolizumab and avelumab, and PD-1-neutralizing antibodies, including nivolumab, pembrolizumab, and dostarlimab, have been used to treat multiple types of cancers such as melanoma, renal cell carcinoma, squamous lung cancer, and metastatic NSCLC [12,13,14].